Anti-A2AP antibodies and uses thereof
AssigneeBayer Aktiengesellschaft
InventorsStefan Heitmeier, Julia Glunz, Melanie Fischer, Cindy Schulenburg, Hannah Jörissen, Christoph Thiel, Andreas Wilmen, Ernst Weber
Life of this patent
Estimating the term…
Abstract
The present invention relates to an isolated antibody or antigen-binding fragment thereof that binds to human A2AP. The isolated antibody or antigen-binding fragment according to the present invention i) cross-reacts with rabbit and/or cynomolgus A2AP, ii) does not inhibit human plasmin activity, and iii) increases plasmin mediated clot lysis in the presence of A2AP.
Claims5
An isolated nucleic acid sequence that encodes an antibody or antigen-binding fragment thereof capable of binding to alpha 2 antiplasmin (A2AP) comprising:
- a heavy chain antigen-binding region that comprises an H-CDR1 comprising SEQ ID NO:
- 6, an H-CDR2 comprising SEQ ID NO:
- 8, and an H-CDR3 comprising SEQ ID NO:
- 13;
- and a light chain antigen-binding region that comprises an L-CDR1 comprising SEQ ID NO:
- 9, an L-CDR2 comprising SEQ ID NO:
- 10, and an L-CDR3 comprising SEQ ID NO:18.
Dependencies are inferred from the claim text.